Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: SNA based therapeutics - Exicure

Next Previous
Search
Drug Profile

Research programme: SNA based therapeutics - Exicure

Alternative Names: SNA constructs - Exicure; SNA targeting IL17RA - Exicure; SNA targeting IL4RA - Exicure; SNA targeting SCN9A - Exicure; Spherical nucleic acid constructs - Exicure

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AuraSense Therapeutics
  • Developer Dermelix Biotherapeutics; Exicure
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Eye disorder therapies; Neuroprotectants; Nucleic acids; Skin disorder therapies
  • Mechanism of Action CLN3 protein expression modulators; Gene modulators; HD protein inhibitors; Immunomodulators; Immunosuppressants; Interleukin 1 beta modulators; Interleukin 4 receptor modulators; Nav1.7 voltage-gated sodium channel modulators; Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain

Highest Development Phases

  • Suspended Angelman syndrome; CNS disorders; Crohn's disease; Neuropathic pain; Ulcerative colitis
  • No development reported Eye disorders; Huntington's disease; Inflammatory bowel diseases; Netherton Syndrome; Respiration disorders; Spinal muscular atrophy
  • Discontinued Amyotrophic lateral sclerosis; Atopic dermatitis; Brain cancer; Epidermolysis bullosa; Fibrosis; Friedreich's ataxia; Lymphoma; Neuronal ceroid lipofuscinosis; Transplant rejection

Most Recent Events

  • 28 Mar 2023 No recent reports of development identified for research development in Netherton-Syndrome in USA
  • 14 Dec 2022 Exciure terminates collaboration agreement with Ipsen
  • 30 Sep 2022 Suspended - Preclinical for CNS disorders in USA (Intrathecal)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top